| abstract |
FIELD: pharmacology. n SUBSTANCE: inventions group relates to a pharmaceutical composition for non-alcoholic fatty liver disease (NAFLD) prevention and treatment including a conjugate prepared by covalent linking of the insulinotropic peptide and the immunoglobulin Fc-fragment by a non-peptidyl polymer in an effective amount and a pharmaceutically acceptable carrier, wherein the non-alcoholic fatty liver disease is selected from the group of simple steatosis, fatty liver diseases caused by malnutrition, starvation, obesity and diabetes, steatohepatitis, liver fibrosis and cirrhosis. A treatment method is also disclosed. n EFFECT: in-vivo retention of peptide activity at a relatively high level and significantly increased half-life of blood, thus preventing accumulation of triglycerides, which is a characteristic feature of non-alcoholic fatty liver disease. n 17 cl, 2 dwg, 1 tbl, 3 ex |